Targeted nanocarrier for wound healing, and method for manufacturing same
Target-directed polymer nanomicelles with a dermal fibroblast-specific ligand address the low absorption issue in existing drug delivery systems, enhancing wound healing by selectively targeting dermal fibroblasts and improving tissue regeneration efficiency.
Patent Information
- Application Number
- PCT/KR2024/005849
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-12
- Filing Date
- 2024-04-30
- Publication Date
- 2024-11-21
AI Technical Summary
Existing passive drug delivery systems for skin wounds face low treatment efficiency due to difficulty in drug absorption into target dermal fibroblasts, leading to slow tissue regeneration and potential side effects from indiscriminate delivery.
Development of target-directed polymer nanomicelles incorporating a dermal fibroblast targeting ligand, specifically a pentapeptide KTTKS, to enhance drug absorption into dermal fibroblasts, using amphiphilic crystalline copolymers and anisotropic lipids like mannosylerythritolipid, forming nano-delivery vehicles that selectively target proteinase-activated receptor (PAR-2) on dermal fibroblast membranes.
The solution significantly increases drug absorption into dermal fibroblasts, promoting rapid tissue regeneration and effective wound healing by enhancing the delivery efficiency of active ingredients to the wound site, while minimizing side effects.
Smart Images

Figure KR2024005849_21112024_PF_FP_ABST
Abstract
Description
Targeted nano-carrier for wound treatment and method for manufacturing the same
[0001] The present invention relates to a target-directed nano-carrier for wound treatment and a method for manufacturing the same, and more particularly, to a drug delivery system based on polymer self-associating nano-micelles introducing a dermal fibroblast-targeting ligand for promoting skin wound healing, and a method for manufacturing the same.
[0002] A wound is a skin disease in which the structure and function of the skin are damaged by injury, acute trauma, or repeated friction in daily life.
[0003] When a wound occurs, early treatment for wound healing and rapid tissue regeneration is very important due to the risk of secondary complications including external infection. Generally, wound healing occurs through four stages: hemostasis, inflammation, proliferation, and remodeling.
[0004] Dermal fibroblasts are the most important cells in the entire wound healing process because they secrete various cytokines, including growth factors, which regulate cell migration and proliferation, extracellular matrix synthesis, angiogenesis, and inflammatory responses.
[0005] Based on this, excellent results have been reported for treatment that directly transplants normal dermal fibroblasts, but there are many difficulties in applying it to patients because the cells that can actually be used are limited.
[0006] This suggests new therapeutic possibilities, such as direct skin absorption or implantation of active ingredients of dermal fibroblast growth factors and stimulating factors (curcumin, niacinamide, EGF, etc.) or drug delivery technologies using nanocarriers or hydrogel dressing formulations. An example of a prior art in this regard is Republic of Korea Patent Publication No. 10-2013-0119674 A (Patent Document 1) (whereby the entire contents of Patent Document 1 are cited and incorporated into the background art contents of the present specification).
[0007] In particular, a drug delivery system using polymer nano-micelles is useful for efficiently dispersing hydrophobic active ingredients in an aqueous solution using an amphiphilic polymer, maintaining long-term stability due to the nano-sized particle size, and easily penetrating the cell membrane to deliver active ingredients into cells.
[0008] However, this system has the disadvantage of having low efficiency of penetration into the complex skin and the possibility of causing side effects due to indiscriminate delivery of effective ingredients, which may actually delay tissue regeneration at the wound site.
[0009] Therefore, it is necessary to develop a formulation technology that can effectively deliver active ingredients to the wound target area to enable rapid tissue regeneration.
[0010] [Prior Art Literature]
[0011] [Patent Document]
[0012] (Patent Document 1) KR10-2013-0119674 A (2013.11.01.)
[0013] Existing passive drug delivery systems for skin tissue have the disadvantage of low therapeutic efficacy due to the presence of many adjacent cells within the skin, which makes drug absorption into target cells difficult.
[0014] Accordingly, the present invention aims to solve the problems of the above-described prior art and establish an active polymer nano-micelle and a manufacturing process thereof that can increase the drug absorption rate into dermal fibroblasts using a targeting ligand for effective healing of a skin wound site as a drug delivery system for wound healing.
[0015] Drug carriers using nano-carriers such as micelles and liposomes or dressings using hydrogels introduced in the prior art are being used for the purpose of wound treatment, but most of them have limitations in demonstrating effective wound healing performance due to low drug delivery efficiency to the target area.
[0016] Accordingly, in the above invention, a target-oriented polymer nano-micelle for dermal fibroblasts, which play an important role in the entire wound healing process, was manufactured to improve drug delivery efficiency and develop an intelligent drug delivery system that enables rapid tissue regeneration at the wound site.
[0017] As a result, a nanocarrier comprising a micelle formed by self-association of an amphiphilic crystalline copolymer and an anisotropic lipid; and a dermal fibroblast-targeting peptide bound to the anisotropic lipid,
[0018] The above anisotropic lipid is mannosylerythritol lipid (MEL)-maleimide,
[0019] A nano-carrier is provided, characterized in that the above dermal fibroblast targeting peptide is a pentapeptide KTTKS (Lys-Thr-Thr-Lys-Ser).
[0020] In addition, a step of dissolving an amphiphilic crystalline copolymer, an anisotropic lipid, and a physiologically active ingredient for dermal fibroblasts in a solvent and stirring the same to obtain a micelle dispersion; and
[0021] A method for manufacturing a nano-carrier is provided, characterized by including a step of adding a dermal fibroblast-targeting peptide to the above micelle dispersion and shaking it.
[0022] Furthermore, a cosmetic composition or pharmaceutical composition for skin regeneration and wound healing comprising the nano-carrier of the present invention is provided.
[0023] The present invention is expected to be actively applied in the pharmaceutical and cosmetic fields because it can be applied to various skin diseases such as atopy and psoriasis as well as wound healing through selective and efficient drug delivery.
[0024] Figure 1 shows CPNV according to the amount of KTTKS introduced (a). KTTSK Particle size and surface potential (■: particle size, ●: surface potential), (b) TEM image and particle size distribution of polymer nano micelles without KTTKS introduction, (c) TEM image and particle size distribution of polymer nano micelles with KTTKS introduction.
[0025] Figure 2 shows (a) cytotoxicity evaluation of polymer nano-micelles according to the amount of KTTKS introduced and (b) quantification of intracellular content.
[0026] Figure 3 shows CPNV for (a) three types of skin cells. KTTSK Target-oriented performance evaluation of (b) CPNV KTTSK Fluorescence imaging of the intracellular distribution of CPNV and (c) CPNV for each cell KTTSK Quantification of content.
[0027] Figure 4, (a) CPNV KTTSK Imaging and (a) quantification of changes in collagen synthesis performance of dermal fibroblasts due to cell uptake.
[0028] Figure 5 shows (a) wound healing evaluation using a mouse model and (b) wound size analysis over time.
[0029] Figure 6 shows the process of conjugating KTTKS peptide to the surface of (a) curcumin-loaded polymer nanomicelles (CPNV), (b) CPNV KTTKS Schematic diagram of the dermal fibroblast infiltration process and drug release mechanism within the cell.
[0030] Hereinafter, the present invention will be described in detail.
[0031]
[0032] The present invention relates to a drug delivery system based on polymer self-associating nanomicelles introducing a dermal fibroblast-targeting ligand for promoting skin wound healing.
[0033] Existing passive drug delivery systems for skin tissue suffer from low therapeutic efficacy due to the presence of numerous adjacent cells within the skin, hindering drug absorption into target cells. Therefore, the present invention provides active polymer nanomicelles that utilize targeting ligands to increase drug absorption into dermal fibroblasts for effective wound healing. The present invention also demonstrates their targeting performance for specific cells and their efficacy in promoting skin wound regeneration.
[0034] In particular, targeting performance was imparted using a KTTKS (Lys-Thr-Thr-Lys-Ser) peptide capable of binding to the proteinase-activated receptor (PAR-2) receptor present in the dermal fibroblast membrane, and then, it was confirmed that the cell uptake rate of the manufactured nanomicelles into dermal fibroblasts increased compared to other cells, and the wound healing promotion effect was verified by loading the active ingredient.
[0035] Figure 6 (a) KTTKS peptide conjugation process on the surface of curcumin-loaded polymer nanomicelles (CPNV), and (b) CPNV KTTKSThe process of dermal fibroblast infiltration and the mechanism of drug release within the cell are shown in a schematic diagram for easy understanding, which can be referred to for understanding.
[0036] As a result, one aspect of the present invention is
[0037] A nano-carrier comprising a micelle formed by self-association of an amphiphilic crystalline copolymer and an anisotropic lipid, and a dermal fibroblast-targeting peptide bound to the anisotropic lipid,
[0038] The above anisotropic lipid is mannosylerythritol lipid (MEL)-maleimide,
[0039] The above dermal fibroblast targeting peptide provides a nano-carrier characterized by being a pentapeptide KTTKS (lysyl-threonyl-threonyl-lysyl-serine).
[0040] Including the above amphiphilic crystalline copolymer and the amphiphilic non-crystalline copolymer, the amphiphilic crystalline copolymer may be at least one selected from the group consisting of, for example, poly(ethylene oxide)-b-poly(ε-caprolactone) copolymer (PEO-b-PCL), PE-b-PCL (poly(ethylene)-b-poly(ε-caprolactone), PHBA-b-PEO (poly(3-hydroxybutyric acid)-b-poly(ethyleneoxide), PEO-b-PAA (poly(ethylene oxide)-b-poly(acrylic acid), PEO-b-PGA (poly(ethylene oxide)-b-poly(glycolic acid), PMPC-b-PBMA (poly(2-methacryloyloxyethyl phosphorylcholine)-b-poly(butylmetacrylate), and PEO-b-PCL-b-PEO (poly(ethylene oxide)-b-poly(ε-caprolactone)-b-poly(ethylene oxide)). However, the present invention is not limited thereto. In one embodiment of the present invention, a PEO-b-PCL-b-PEO copolymer is used and may be preferably selected, but is not necessarily limited thereto.
[0041] The above anisotropic lipid serves as a linker for the dermal fibroblast-targeting peptide, and mannosylerythritol lipid (MEL)-maleimide can be preferably selected. By replacing the hydroxyl group of the anisotropic lipid with a peptide linker and utilizing the maleimide-thiol reaction, which is a representative reaction of peptide conjugation, a micelle conjugated with the dermal fibroblast-targeting peptide can be prepared, but is not necessarily limited thereto, and a method widely known to those skilled in the art can be used.
[0042] The content of the anisotropic lipid may be 5 to 40 wt% based on the total weight of the entire micelle, and preferably 5 to 30 wt%. When the content of the anisotropic lipid is less than 5 wt%, there is a problem that the linker role of the dermal fibroblast-targeting peptide is insufficient, and when it exceeds 40 wt%, the content of other phases is relatively low, which is not preferable in terms of micelle structure formation, and when the anisotropic lipid in the micelle exceeds a certain concentration, the polymer and lipid phases may separate.
[0043] The above dermal fibroblast targeting peptide may preferably be pentapeptide KTTKS (lysyl-threonyl-threonyl-lysyl-serine). The pentapeptide KTTKS (lysyl-threonyl-threonyl-lysyl-serine) is a part of collagen type I that plays an important role in elasticity and moisturizing in the dermal layer of the skin. It is known to promote the production of growth factor TGF-β by inhibiting collagenase and maintaining extracellular matrix (ECM) and collagen type I biosynthesis and intracellular mRNA stability through its role as a 'signal peptide' within cells, and the above KTTKS forms cell-specific ligand bonds with receptors overexpressed on the surface of fibroblasts (PAR-2).
[0044] The content of the dermal fibroblast-targeting peptide may be 1 μM to 300 μM, preferably 5 μM to 200 μM, more preferably 25 μM to 200 μM, and even more preferably 25 μM to 100 μM. If the content of the dermal fibroblast-targeting peptide is less than 1 μM, there may be a problem of minimal effect, and if it exceeds 300 μM, there may be a problem of cytotoxicity. The higher the peptide content, the more advantageous it is in terms of expressing the target-directed effect, but in particular, when it exceeds 200 μM, a phenomenon in which cytotoxicity increases somewhat appears. Unlike forms such as liposomes, micelle-type nanocarriers may exhibit strong toxicity as they have good penetrability, so it may be necessary to adjust the concentration content value. A more detailed understanding of this can be obtained through the examples and test examples described below.
[0045] The nano-carrier of the present invention may further include a physiologically active ingredient for dermal fibroblasts inside the micelle.
[0046] The physiologically active ingredient for the above dermal fibroblasts is not particularly limited and any known ingredient can be used without limitation, but a fat-soluble ingredient is preferred, and non-limiting examples thereof include beta-carotene compounds (including vitamin A and precursor components), vitamin E compounds (including tocopherol), curcumin, etc., and curcumin is preferred.
[0047] The average particle size of the micelles is not particularly limited and can be adjusted in various ways depending on the type and size of the transport target substance to be encapsulated, but an appropriate range can be set by considering issues such as toxicity and penetration ability. That is, when the particle size of the micelles is less than 2 nm, the content of the physiologically active substance is low compared to the nanocarrier, so there may be a possibility of toxicity problems due to absorption in the human body. When the particle size exceeds 500 nm, there may be difficulty in passing through the stratum corneum to reach the dermis layer, and there may be a possibility of particle instability problems.
[0048] Accordingly, although a range of 2 to 500 nm can be used, the average particle diameter of the preferred micelle may be 10 to 100 nm, more preferably 20 to 100 nm, and even more preferably 25 to 75 nm.
[0049] In addition, another aspect of the present invention is a method for manufacturing a nano-carrier.
[0050] In particular, based on an understanding of the fundamental wound healing mechanism, the present invention fabricates a drug delivery system using polymer nanomicelles incorporating a dermal fibroblast-targeting peptide (KTTKS, Lys-Thr-Thr-Lys-Ser) for wound healing applications. Specifically, polymer nanomicelles are fabricated by self-association of the amphiphilic polymer PEO-b-PCL and MEL-maleimide lipid, and the surface of the polymer nanomicelles is engineered with the KTTKS peptide through a thiol-maleimide reaction. This promotes cellular uptake by inducing the polymer nanomicelles to selectively target the proteinase-activated receptor (PAR-2), which exists only on the cell membrane of dermal fibroblasts. As a result, the drug can be effectively delivered to dermal fibroblasts at the wound site and a system advantageous for wound healing can be fabricated by inducing rapid tissue regeneration at the site.
[0051] The specific technical content is as follows. (1) It consists of a process for manufacturing polymer nano micelles using an amphiphilic polymer and anisotropic lipids, and (2) a process for introducing KTTKS, a dermal fibroblast-targeting ligand, onto the surface of the manufactured polymer nano micelles.
[0052] As a result, the manufacturing method of the present invention,
[0053] A step of dissolving an amphiphilic crystalline copolymer, an anisotropic lipid, and a physiologically active ingredient for dermal fibroblasts in a solvent and stirring the same to obtain a micelle dispersion; and
[0054] It is characterized by including a step of adding a dermal fibroblast targeting peptide to the above micelle dispersion and shaking it.
[0055] Here, the anisotropic lipid may be mannosylerythritol lipid (MEL)-maleimide, and the dermal fibroblast targeting peptide may be pentapeptide KTTKS (Lys-Thr-Thr-Lys-Ser).
[0056] In addition, the solvent may be any organic solvent known in the art, without limitation. However, tetrahydrofuran (THF) is more preferably selected because it dissolves well not only in lipid-soluble substances but also in water-soluble substances such as water, thereby contributing to the stabilization of amphiphilic crystalline copolymers and anisotropic lipids, and enhancing the affinity of physiologically active ingredients for dermal fibroblasts within micelles.
[0057] The above dermal fibroblast targeting peptide is pentapeptide KTTKS (lysyl-threonyl-threonyl-lysyl-serine) and is preferably 300 μM or less. As described above, if it exceeds 300 μM, there is a possibility of significant cytotoxicity.
[0058]
[0059] Furthermore, another aspect of the present invention is
[0060] A cosmetic composition for skin regeneration and wound healing comprising the nano-carrier of the present invention is described. The nano-carrier of the present invention is in the form of micelles, and is suitable for use in cosmetic compositions due to its excellent penetration ability and high stability. In particular, its excellent direct skin penetration ability makes it suitable for use in topical skin compositions.
[0061] The cosmetic composition of the present invention may be in the form of an emulsion, lotion, ointment, patch, spray, cream (oil-in-water, water-in-oil, multiphase), solution, suspension (anhydrous and aqueous), anhydrous product (oil and glycol), gel, mask, pack, or powder, and the form thereof is not particularly limited.
[0062] More specifically, the cosmetic composition of the present invention may have any one formulation selected from the group consisting of external skin ointment, cream, emollient toner, nourishing toner, pack, essence, hair tonic, shampoo, rinse, hair conditioner, hair treatment, gel, skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nourishing lotion, massage cream, nourishing cream, moisture cream, hand cream, foundation, nourishing essence, sunscreen, soap, cleansing foam, cleansing lotion, cleansing cream, body lotion, and body cleanser, but is not limited thereto. The cosmetic composition composed of each of these formulations may contain various bases and additives necessary and appropriate for the formulation of the formulation, and the types and amounts of these ingredients can be easily selected by a person skilled in the art.
[0063] In addition, the cosmetic composition of the present invention may additionally contain excipients such as fluorescent substances, fungicides, hydrotropism inducers, moisturizers, fragrances, fragrance carriers, proteins, solubilizers, sugar derivatives, sunscreens, vitamins, and plant extracts.
[0064] The content of the nano-carrier of the present invention in the above cosmetic composition can be appropriately adjusted by a person skilled in the art as needed, but it is preferably included in an amount of 0.1 to 20 wt% based on the total weight of the composition. If it is included in an amount less than 0.1 wt%, the effect may be minimal, and if it is included in an amount exceeding 20 wt%, there may be problems such as ease of handling during the formulation process, storage stability, and cost issues, which may be somewhat undesirable.
[0065]
[0066] Furthermore, another aspect of the present invention is
[0067] A pharmaceutical composition for skin regeneration and wound healing comprising the nano-carrier of the present invention as an active ingredient.
[0068] The nano-carrier of the present invention is in the form of micelles, has good penetration ability and high stability, and is therefore suitable for use in pharmaceutical compositions. In particular, it has excellent direct skin penetration ability, and is therefore suitable for use in compositions for external skin applications.
[0069] The pharmaceutical composition of the present invention can be manufactured in a unit dose form or can be manufactured by inserting it into a multi-dose container by formulating it using a pharmaceutically acceptable carrier and / or excipient according to a method that can be easily performed by a person having ordinary skill in the art to which the present invention pertains. In this case, the formulation may be in the form of a solution, suspension or emulsion in an oil or aqueous medium, or in the form of an extract, powder, granules, tablet or capsule, and may additionally include a dispersing agent or stabilizer.
[0070] The pharmaceutical composition of the present invention may include, in addition to the active ingredient, a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers included in the pharmaceutical composition of the present invention are those commonly used in formulations, and include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. In addition to the above components, the pharmaceutical composition of the present invention may further include lubricants, wetting agents, sweetening agents, flavoring agents, emulsifiers, suspending agents, preservatives, and the like. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington's Pharmaceutical Sciences (19th ed, 1995).
[0071] The appropriate dosage of the pharmaceutical composition of the present invention may vary depending on factors such as the formulation method, administration method, patient age, body weight, sex, pathological condition, food, administration time, administration route, excretion rate, and response sensitivity. Meanwhile, the dosage of the pharmaceutical composition of the present invention is preferably 0.0001-1000 mg / kg (body weight) per day.
[0072] Administration may be by topical application, intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, or transdermal administration. When the pharmaceutical composition of the present invention is provided as a pharmaceutical composition specifically targeting skin cells, administration may be by topical application to the skin, but is not limited thereto. When the pharmaceutical composition of the present invention is in the form of a skin external formulation, the skin external formulation is not particularly limited, but is preferably a powder, gel, ointment, cream, liquid, or aerosol formulation.
[0073] In the present invention, as a gel base material of a skin external preparation, one or more selected from among Carbopol, Carbomer, Polyethyleneglycol, Polypropylene glycol, Polyacrylic acid, Carboxymethyl cellulose, Hydroxymethylcellulose, Polyvinylpyrrolidone, Gelatin, Alginate Salt, Chitin or Chitosan derivatives, hyaluronic acid, and collagen may be used, but is not limited thereto.
[0074]
[0075]
[0076]
[0077] Hereinafter, the present invention will be described in more detail with examples. However, it should be made clear that the following examples are intended only to provide a detailed explanation of the invention and are not intended to limit the scope of the rights herein.
[0078]
[0079] Example
[0080] Manufacturing of micelles
[0081] Amphiphilic polymer PEO-b-PCL (PEO: 50,000 g / mol, PCL: 20,000 g / mol), MEL-maleimide lipid, and curcumin as an active ingredient were dissolved in THF organic solvent at 40°C for 10 minutes and then placed in a round-bottom flask. Then, DI water was added to the mixture at a rate of 100 μL / min using a syringe pump while stirring. After the formation of polymer nanomicelles, THF was completely removed from the dispersion using a rotary evaporator at 40°C for 20 minutes. The final prepared solution was passed through a 0.1 μm syringe filter to prepare polymer nanomicelles with a size of approximately 50 nm.
[0082] Introduction of targeting peptides
[0083] KTTKS peptides at various concentrations (25 μM, 50 μM, 100 μM, 200 μM) were quantitatively added to the prepared polymer nanomicelle dispersion and allowed to react on a shaker at room temperature for more than 12 hours to ensure sufficient synthesis. The nanomicelles thus obtained were diluted in a DMEM (Dulbecco Modified Egale Medium) solution at the desired ratio and used in cell experiments.
[0084]
[0085] Comparative example
[0086] To determine the targeting performance toward dermal fibroblasts according to the amount of KTTKS introduced on the surface of polymer nano micelles, a polymer nano micelle sample without KTTKS was set as a control group.
[0087]
[0088] Polymer typeCurcumin concentration (wt%)KTTKS concentration (μM)Comparative examplePEO 5k -b-PCL 2k 0.010 Example 1PEO 5k -b-PCL 2k 0.0125 Example 2PEO5k -b-PCL 2k 0.0150 Example 3PEO 5k -b-PCL 2k 0.01100 Example 4PEO 5k -b-PCL 2k 0.01200 Example 5PEO 5k -b-PCL 2k 025 Example 6PEO 5k -b-PCL 2k 050 Example 7PEO 5k -b-PCL 2k 0100 Example 8PEO 5k -b-PCL 2k 0200
[0089] Exam example
[0090] <Example 1>
[0091] As shown in Table 2 below, when the size and surface potential were measured before and after the introduction of the peptide on the surface of the polymer nano micelles, both the polymer nano micelles before and after the introduction of the peptide showed a size of approximately 50 nm, and the surface potential increased from approximately -9 mV to -2 mV as the KTTKS peptide was attached. In addition, as shown in Fig. 1, the morphology of the polymer nano micelles before and after the introduction of the peptide was observed using a transmission electron microscope (TEM) to confirm the structure and size distribution of the micelles.
[0092] Particle size (nm) Surface potential (mV) Comparative example 48.8-8.7 Example 1 49.3-5.7 Example 2 50.9-4.6 Example 3 51.2-3.5 Example 4 54.2-2.0
[0093] <Example 2>
[0094] After treating dermal fibroblasts with the polymer nano micelles of Examples 5 to 8 for 24 hours and then treating them with the EZ-Cytox solution, the absorbance was measured using a microplate reader, and it was confirmed that the polymer nano micelles were not toxic to the cells.
[0095] Additionally, during the manufacture of polymer nano-micelles, Texas Red-DHPE fluorescent material was added, and nano-micelles containing KTTKS peptide at various concentrations were treated with dermal fibroblasts for 24 hours, after which fluorescence intensity was measured. The results confirmed that the absorption trend increased with increasing peptide concentration. The results are shown in Figure 2.
[0096]
[0097] <Example 3>
[0098] Based on the concentration with the highest cell uptake confirmed in Test Example 2, the sample was treated on three types of mixed skin cells (dermal fibroblasts, melanocytes, and keratinocytes) and the fluorescence intensity was measured using a microplate reader to analyze the uptake rate for each cell. As a result, it was confirmed that the highest cell uptake was shown in dermal fibroblasts. The results are shown in Fig. 3.
[0099]
[0100] <Example 4>
[0101] Examples 1 to 4, in which polymer micelles loaded with curcumin, known to promote collagen synthesis in dermal fibroblasts, were prepared and KTTKS was introduced onto the surface, were applied to dermal fibroblasts, and their efficacy was quantitatively evaluated. As a result, it was confirmed that collagen synthesis increased as the amount of KTTKS introduced increased. The results are shown in Fig. 4.
[0102]
[0103] <Example 5>
[0104] To confirm the wound healing performance in actual tissues, curcumin, curcumin-loaded polymeric micelles (CPNV), and polymeric micelles (CPNV) of Examples 1 to 4 loaded with curcumin and introduced with KTTKS peptide were applied to a mouse wound model. KTTKS) were treated respectively and the change in wound size over time was observed. As a result, it was confirmed that the peptide-introduced polymer nano micelles of Examples 1 to 4 had excellent skin regeneration ability in the wound tissue area. The results are shown in Fig. 5.
[0105] The present invention is suitable for use as an external skin preparation and can be used in the fields of cosmetics, pharmaceuticals, and quasi-drugs.
Claims
1. A nano-carrier comprising a micelle formed by self-association of an amphiphilic crystalline copolymer and an anisotropic lipid, and a dermal fibroblast-targeting peptide bound to the anisotropic lipid, The above anisotropic lipid is mannosylerythritol lipid (MEL)-maleimide, A nano-carrier characterized in that the above dermal fibroblast targeting peptide is a pentapeptide KTTKS (Lys-Thr-Thr-Lys-Ser).
2. A nano-carrier according to claim 1, wherein the amphiphilic crystalline copolymer is a poly(ethylene oxide)-b-poly(ε-caprolactone) copolymer (PEO-b-PCL).
3. A nano-carrier according to claim 1, characterized in that the pentapeptide KTTKS has a concentration of 300 μM or less.
4. A nano-carrier according to claim 1, characterized in that it further comprises a physiologically active ingredient for dermal fibroblasts inside the micelle.
5. A nano-carrier according to claim 4, characterized in that the physiologically active ingredient for the dermal fibroblasts is curcumin.
6. A nano-carrier according to claim 1, characterized in that the average particle diameter of the micelle is 20 to 100 nm.
7. A step of dissolving an amphiphilic crystalline copolymer, an anisotropic lipid, and a physiologically active ingredient for dermal fibroblasts in a solvent and stirring the same to obtain a micelle dispersion; and A step of adding a dermal fibroblast targeting peptide to the above micelle dispersion and shaking, The above anisotropic lipid is mannosylerythritol lipid (MEL)-maleimide, A method for producing a nano-carrier, characterized in that the above dermal fibroblast targeting peptide is a pentapeptide KTTKS (Lys-Thr-Thr-Lys-Ser).
8. A method for producing a nano-carrier according to claim 7, characterized in that the solvent is tetrahydrofuran (THF).
9. A method for producing a nano-carrier according to claim 7, wherein the dermal fibroblast targeting peptide is a pentapeptide KTTKS (lysyl-threonyl-threonyl-lysyl-serine) and has a concentration of 300 μM or less.
10. A method for producing a nano-carrier according to claim 7, characterized in that the physiologically active ingredient for the dermal fibroblasts is curcumin.
11. A method for manufacturing a nano-carrier according to claim 7, characterized in that the average particle diameter of the micelle is 20 to 100 nm.
12. A cosmetic composition for skin regeneration and wound healing comprising the nano-carrier of claim 1 or claim 4.
13. A pharmaceutical composition for skin regeneration and wound healing comprising the nano-carrier of claim 1 or claim 4.
Citation Information
Patent Citations
Mushroom cultivation system
KR1020210109930A
Suspension for membrane structure
KR102189606B1
Apparatus For Fitting Floating Pots For Aquatic Plant
KR102260567B1
KR20220147163A
